Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001847367-25-000050
Filing Date
2025-11-13
Accepted
2025-11-13 16:40:23
Documents
96
Period of Report
2025-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q alms-20250930x10q.htm   iXBRL 10-Q 3152694
2 EX-10.1 alms-20250930xex10d1.htm EX-10.1 71423
3 EX-31.1 alms-20250930xex31d1.htm EX-31.1 15388
4 EX-31.2 alms-20250930xex31d2.htm EX-31.2 14892
5 EX-32.1 alms-20250930xex32d1.htm EX-32.1 9683
6 EX-32.2 alms-20250930xex32d2.htm EX-32.2 9106
  Complete submission text file 0001847367-25-000050.txt   12957840

Data Files

Seq Description Document Type Size
7 EX-101.SCH alms-20250930.xsd EX-101.SCH 95108
8 EX-101.CAL alms-20250930_cal.xml EX-101.CAL 85392
9 EX-101.DEF alms-20250930_def.xml EX-101.DEF 422165
10 EX-101.LAB alms-20250930_lab.xml EX-101.LAB 796350
11 EX-101.PRE alms-20250930_pre.xml EX-101.PRE 626200
99 EXTRACTED XBRL INSTANCE DOCUMENT alms-20250930x10q_htm.xml XML 2177215
Mailing Address 280 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 280 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 650-231-6625
ALUMIS INC. (Filer) CIK: 0001847367 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-42143 | Film No.: 251479254
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)